Form 4: REVB CFO Reports Mandatory Tax Withholding Sale

Revelation Biosciences CFO Chester S. Zygmont III reported the sale of 13,285 shares to satisfy tax obligations related to restricted stock vesting.

Summary

• Chester S. Zygmont III, CFO of Revelation Biosciences, Inc., disposed of 13,285 shares of common stock.
• The transaction occurred on April 30, 2026, at a weighted average price of $1.10 per share.
• The sale was mandatory and executed by the issuer to cover tax withholding obligations upon the vesting of restricted stock awards.
• The reporting person retained no investment discretion over this specific transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and mandatory for tax purposes.

Positives

• The transaction was a non-discretionary event required for tax compliance, indicating no change in the executive's long-term outlook on the company.

Negatives

• Reduction in the total number of shares beneficially owned by the reporting person.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

Not applicable; this is a historical disclosure of a past transaction.

Industry Context

StockSavvy.ai notes that mandatory tax withholding sales are standard corporate governance practices for executives receiving equity-based compensation and do not typically signal a change in management sentiment.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive equity compensation vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover.

Key Dates

Keywords

REVB, Revelation Biosciences, Insider Trading, Form 4, Tax Withholding, CFO